P and T最新文献

{"title":"Using Information on Patient Adherence to Antipsychotic Medication to Understand Their Adherence to Other Medications.","authors":"Jason Shafrin,&nbsp;Alison R Silverstein,&nbsp;Joanna P MacEwan,&nbsp;Darius N Lakdawalla,&nbsp;Ainslie Hatch,&nbsp;Felicia M Forma","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>To assess how patient adherence to atypical antipsychotic medications is associated with adherence to concurrently used medications that treat other serious mental illnesses (SMIs), type-2 diabetes, or hypertension.</p><p><strong>Methods: </strong>Among patients who had been diagnosed with an SMI (i.e., bipolar disorder, major depressive disorder, or schizophrenia) in the previous year, we used health-insurance claims data to measure adherence based on medication fills. Patients diagnosed with an SMI were required to have 1) a prescription for an atypical oral antipsychotic, and 2) another SMI therapy or oral anti-diabetic or antihypertensive agent in the same year. The patient's concurrent adherence to an antipsychotic and one of 23 other medications was measured by the proportion of days covered (PDC) over a one-year period. Patients were considered adherent when the PDC was ≥ 80%. The strength of the association between their atypical antipsychotic adherence and their concurrent medication adherence was evaluated using the following metrics: accuracy, positive predictive value (PPV), and negative predictive value (NPV).</p><p><strong>Results: </strong>The average (standard deviation) age of patients (N = 129,614) was 44.8 (14.8) years and 62.2% of patients were female. The median accuracy based on atypical antipsychotic adherence to the other 23 medications was 67% (range, 55-71%; statistically different from 50% accuracy in all cases, <i>P</i> < 0.001). Accuracy was higher than physician predictions of adherence from previous studies (53%). The negative predictive value of antipsychotic adherence (75%; range, 62-88%) was generally higher than the PPV (62%; range, 43-67%; all, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Information on patient adherence to antipsychotics provides significant insight into adherence to other medications often used by patients with SMI. Because NPV is higher than PPV, adherence to antipsychotics is likely to be a necessary but not sufficient condition for patients with SMI regarding adherence to non-SMI medications.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"350-357"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534179/pdf/ptj4406350.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Article on Hospital Consolidation Misleads.","authors":"Melinda Hatton","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"319"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534169/pdf/ptj4406319.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Drug Pricing \"Transparency\" Bill With Strong Bipartisan Support But Would It Accomplish Much?","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several drug-price \"remedy\" bills are floating around Congress, with most being described as a \"first step.\" So why is no one referring to that step as significant?</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"323"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534173/pdf/ptj4406323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug and Device News.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Approvals, new indications and formulations, and safety issues.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"324-336"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534178/pdf/ptj4406324.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous Versus Oral Acetaminophen in Ambulatory Surgical Center Laparoscopic Cholecystectomies: A Retrospective Analysis.","authors":"Ryan J Johnson,&nbsp;Danny K Nguyen,&nbsp;Jose M Acosta,&nbsp;Alice L O'Brien,&nbsp;Peter D Doyle,&nbsp;Glorimar Medina-Rivera","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Study objective: </strong>The primary aim was to compare postoperative pain scores in patients undergoing laparoscopic cholecystectomy and receiving intravenous (IV) or oral (PO) acetaminophen (APAP) as part of a multimodal analgesic regimen to examine whether PO APAP is non-inferior to IV APAP.</p><p><strong>Design: </strong>Retrospective analysis.</p><p><strong>Setting: </strong>Ambulatory surgical center (ASC) in an academic setting.</p><p><strong>Patients: </strong>579 patients (18-70 years old), American Society of Anesthesiologists physical status I-III, undergoing laparoscopic cholecystectomy.</p><p><strong>Interventions: </strong>Patients received 1,000 mg IV APAP intraoperatively (n = 319) or 1,000 mg PO APAP preoperatively (n = 260).</p><p><strong>Measurements: </strong>The primary outcome was the median difference in post-anesthesia care unit (PACU) end-pain scores between the groups. Median pain scores were also compared on PACU admission, and at 15, 30, 45, and 60 minutes. Additional measures include PACU rescue-analgesia consumption, time to first PACU rescue analgesia, intraoperative use of opioid and nonopioid analgesics, PACU length of stay, and PACU rescue nausea and vomiting therapy.</p><p><strong>Main results: </strong>In both groups, the PACU median end-pain score was 2. The 90% confidence interval (CI) for difference in median pain scores between groups was [0, 0]; the CI upper limit was below the non-inferior margin of 1 pain-score point, indicating PO APAP's non-inferiority to IV APAP. There were no statistically significant differences in the percentages of patients receiving PACU hydromorphone equivalents between the IV and PO groups (75% vs. 77%, <i>P</i> = 0.72) or in the mean dose received (0.5 mg vs. 0.5 mg, <i>P</i> = 0.66).</p><p><strong>Conclusion: </strong>Single-dose PO APAP is non-inferior to IV APAP for postoperative analgesia in ASC laparoscopic cholecystectomy patients. The value of single-dose IV APAP in this population should be further explored.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"359-363"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534170/pdf/ptj4406359.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical Approval Update.","authors":"Michele B Kaufman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Sunosi (solriamfetol) tablets for excessive daytime sleepiness with narcolepsy or obstructive sleep apnea; Zulresso (brexanolone) injection for postpartum depression in adults; Mayzent (siponimod) tablets for adults with relapsing forms of MS.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"337-339"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534175/pdf/ptj4406337.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intranasal Esketamine (Spravato^TM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.","authors":"Rebecca Bahr,&nbsp;Alicia Lopez,&nbsp;Jose A Rey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Intranasal esketamine for treatment-resistant depression.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"340-375"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534172/pdf/ptj4406340.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Association for the Study of the Liver The International Liver Congress 2019.","authors":"Walter Alexander","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We cover key sessions on hepatitis B, C, and D virus infections, hepatocellular carcinoma, nonalcoholic steatohepatitis, acute hepatic porphyria, and liver growth in polycystic kidney disease.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"365-369"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534177/pdf/ptj4406365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) Therapy.","authors":"Lindsey M Fovel,&nbsp;Christopher D Miller,&nbsp;Robert W Seabury,&nbsp;Luke A Probst,&nbsp;Lara Horvath","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 6","pages":"364"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534174/pdf/ptj4406364.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37299466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FTC Gives Generics Victory On \"Pay for Delay\": Reverse Payments Crimped, Patent Thickets Untouched.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>How easy is it for generics to enter the market? It could be easier with legislation that opens up the field for generic competitors, but it is unlikely that such a bill will ever be introduced.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 5","pages":"234-266"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487975/pdf/ptj4405234.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37236013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}